SCHEMBL2943652

SCHEMBL2943652

CC1(C)OCCC(c2cccc(Br)c2)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 5/20 0.40
HCRTR2 O43614 5/20 0.40
KDM1A O60341 4/20 0.39
RCOR1 Q9UKL0 2/20 0.38
MAPT P10636 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
DRD3 P35462 1/20 0.38
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
SLC6A4 P31645 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10798707 0.80 TSHR (0.42) HCRTR1HCRTR2KDM1ASLC6A2SLC6A4
SCHEMBL2948970 0.77 KMO (0.48) HCRTR1HCRTR2KDM1ADRD3
SCHEMBL9035063 0.73 CYP2A6 (0.48) MAPTCHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL28642739 0.72 HTR2B (0.37) HCRTR1HCRTR2KDM1ARCOR1SLC6A2
SCHEMBL5856089 0.71 HCRTR1 (0.43) HCRTR1HCRTR2KDM1ARCOR1MAPT
SCHEMBL2945319 0.71 HTR1A (0.36) KDM1AHTR2B
SCHEMBL1813507 0.70 KDM1A (0.44) HCRTR1HCRTR2KDM1ARCOR1MAPT
SCHEMBL27997313 0.69 KDM1A (0.44) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL7784351 0.69 TSHR (0.54) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL29364885 0.69 TSHR (0.54) KDM1ARCOR1DRD2DRD1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076367-B2 Benzimidazolylidene propane-1,3-dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-12-13 US disclosed
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2010-07-08 US disclosed
US-7709519-B2 Benzimidazolylidene propane-1,3 dione derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2010-05-04 US disclosed
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof ASTELLAS PHARMA INC. (JP) 2009-01-15 US disclosed
EP-1752452-A9 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-12-12 EP disclosed
EP-1752452-A1 PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT Astellas Pharma Inc. (JP) 2007-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018177-A1 Propane-1,3-Dione Derivative or Salt Thereof GPER1, GNRHR, AR HCRTR1 1085/4885HCRTR2 1367/4885KDM1A 285/4885
US-20100173946-A1 BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF GPER1, GNRHR, AR HCRTR1 1145/4885HCRTR2 1305/4885KDM1A 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.